{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:50:21Z","timestamp":1791910221971,"version":"4.3.4"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41575-024-01019-7","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:37:34Z","timestamp":1733960254000},"page":"112-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-9619","authenticated-orcid":false,"given":"Evangelos","family":"Triantafyllou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin L. C.","family":"Gudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia A.","family":"Possamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison, A., Garaud, S., Chiche, L., Cornec, D. & Kostine, M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat. Rev. Rheumatol. 18, 641\u2013656 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang, S. J., Dougan, S. K. & Dougan, M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9, 543\u2013553 (2023).","journal-title":"Trends Cancer"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F. & Eggermont, A. M. M. Clinical and translational attributes of immune-related adverse events. Nat. Cancer 5, 557\u2013571 (2024).","journal-title":"Nat. Cancer"},{"key":"1019_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01365-3","volume":"28","author":"P Ding","year":"2023","unstructured":"Ding, P., Liu, P., Meng, L. & Zhao, Q. Mechanisms and biomarkers of immune-related adverse events in gastric cancer. Eur. J. Med. Res. 28, 492 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.esmogo.2023.08.004","volume":"1","author":"F van B\u00f6mmel","year":"2023","unstructured":"van B\u00f6mmel, F., Berg, T. & Lordick, F. Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC). ESMO Gastrointest. Oncol. 1, 27\u201339 (2023).","journal-title":"ESMO Gastrointest. Oncol."},{"key":"1019_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09115-6","volume":"22","author":"V Schlintl","year":"2022","unstructured":"Schlintl, V. et al. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC Cancer 22, 51 (2022).","journal-title":"BMC Cancer"},{"key":"1019_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1019_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa, L., Finn, R. S. & Sangro, B. Combination immunotherapy for hepatocellular carcinoma. J. Hepatol. 79, 506\u2013515 (2023).","journal-title":"J. Hepatol."},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B. et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35, 448\u2013457 (2024).","journal-title":"Ann. Oncol."},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR11","doi-asserted-by":"publisher","first-page":"ITC17","DOI":"10.7326\/AITC202402200","volume":"177","author":"M Ramos-Casals","year":"2024","unstructured":"Ramos-Casals, M. & Sis\u00f3-Almirall, A. Immune-related adverse events of immune checkpoint inhibitors. Ann. Intern. Med. 177, ITC17\u2013ITC32 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1019_CR12","doi-asserted-by":"publisher","first-page":"794099","DOI":"10.3389\/fimmu.2021.794099","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Correlation between immune-related adverse events and prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. Front. Immunol. 12, 794099 (2021).","journal-title":"Front. Immunol."},{"key":"1019_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1055\/s-0043-1776761","volume":"43","author":"CLC Gudd","year":"2023","unstructured":"Gudd, C. L. C., Sheth, R., Thursz, M. R., Triantafyllou, E. & Possamai, L. A. Immune checkpoint inhibitor-induced liver injury. Semin. Liver Dis. 43, 402\u2013417 (2023).","journal-title":"Semin. Liver Dis."},{"key":"1019_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR17","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"1019_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1019_CR19","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy \u2014 current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1019_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1126\/sciimmunol.adf2223","volume":"9","author":"KO Dixon","year":"2024","unstructured":"Dixon, K. O., Lahore, G. F. & Kuchroo, V. K. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells. Sci. Immunol. 9, 2223 (2024).","journal-title":"Sci. Immunol."},{"key":"1019_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N., Anderson, A. C. & Kuchroo, V. K. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"1019_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"1019_CR24","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20220007","volume":"4","author":"VA Boussiotis","year":"2022","unstructured":"Boussiotis, V. A. & Patsoukis, N. Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism 4, e220007 (2022).","journal-title":"Immunometabolism"},{"key":"1019_CR25","doi-asserted-by":"publisher","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","volume":"5","author":"L Strauss","year":"2020","unstructured":"Strauss, L. et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci. Immunol. 5, eaay1863 (2020).","journal-title":"Sci. Immunol."},{"key":"1019_CR26","doi-asserted-by":"publisher","first-page":"eabf4034","DOI":"10.1126\/sciimmunol.abf4034","volume":"6","author":"JR Kuchroo","year":"2021","unstructured":"Kuchroo, J. R., Hafler, D. A., Sharpe, A. H. & Lucca, L. E. The double-edged sword: harnessing PD-1 blockade in tumor and autoimmunity. Sci. Immunol. 6, eabf4034 (2021).","journal-title":"Sci. Immunol."},{"key":"1019_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442\u2013454 (2020).","journal-title":"Nat. Immunol."},{"key":"1019_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495\u2013499 (2017).","journal-title":"Nature"},{"key":"1019_CR29","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.1073\/pnas.0809422106","volume":"106","author":"X Huang","year":"2009","unstructured":"Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303\u20136308 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1019_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140196","volume":"131","author":"E Triantafyllou","year":"2021","unstructured":"Triantafyllou, E. et al. PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. J. Clin. Invest. 131, e140196 (2021).","journal-title":"J. Clin. Invest."},{"key":"1019_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","volume":"24","author":"A Christofides","year":"2023","unstructured":"Christofides, A. et al. SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses. Nat. Immunol. 24, 55\u201368 (2023).","journal-title":"Nat. Immunol."},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e17 (2017).","journal-title":"Cell"},{"key":"1019_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5230\/jgc.2023.23.e10","volume":"23","author":"J Yoon","year":"2023","unstructured":"Yoon, J., Kim, T.-Y. & Oh, D.-Y. Recent progress in immunotherapy for gastric cancer. J. Gastric Cancer 23, 207 (2023).","journal-title":"J. Gastric Cancer"},{"key":"1019_CR35","doi-asserted-by":"publisher","first-page":"705999","DOI":"10.3389\/fimmu.2021.705999","volume":"12","author":"D-K Wang","year":"2021","unstructured":"Wang, D.-K., Zuo, Q., He, Q.-Y. & Li, B. Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front. Immunol. 12, 705999 (2021).","journal-title":"Front. Immunol."},{"key":"1019_CR36","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2022","unstructured":"Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J. Clin. Oncol. 41, 1213\u20131227 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1019_CR38","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"1019_CR39","doi-asserted-by":"publisher","first-page":"ltac008","DOI":"10.1093\/immadv\/ltac008","volume":"2","author":"GF de Britto Evangelista","year":"2022","unstructured":"de Britto Evangelista, G. F., Figueiredo, A. B., de Barros e Silva, M. J. & Gollob, K. J. Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. Immunother. Adv. 2, ltac008 (2022).","journal-title":"Immunother. Adv."},{"key":"1019_CR40","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin, Q. et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front. Immunol. 14, 1167975 (2023).","journal-title":"Front. Immunol."},{"key":"1019_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1019_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","volume":"7","author":"EC De Moel","year":"2019","unstructured":"De Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6\u201311 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1019_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30863-x","volume":"13","author":"AJ Patel","year":"2022","unstructured":"Patel, A. J. et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat. Commun. 13, 3148 (2022).","journal-title":"Nat. Commun."},{"key":"1019_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","volume":"28","author":"AX Lozano","year":"2022","unstructured":"Lozano, A. X. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 353\u2013362 (2022).","journal-title":"Nat. Med."},{"key":"1019_CR45","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir, S. A. et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl Acad. Sci. USA 116, 22246\u201322251 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1019_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386362","volume":"7","author":"H L\u00e4ubli","year":"2018","unstructured":"L\u00e4ubli, H. et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology 7, e1386362 (2018).","journal-title":"Oncoimmunology"},{"key":"1019_CR47","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"L Flatz","year":"2019","unstructured":"Flatz, L. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043\u20131047 (2019).","journal-title":"JAMA Oncol."},{"key":"1019_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88824-1","volume":"11","author":"S Hagiwara","year":"2021","unstructured":"Hagiwara, S. et al. Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. Sci. Rep. 11, 9242 (2021).","journal-title":"Sci. Rep."},{"key":"1019_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","volume":"20","author":"RC Simpson","year":"2023","unstructured":"Simpson, R. C., Shanahan, E. R., Scolyer, R. A. & Long, G. V. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 20, 697\u2013715 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1019_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01285-9","volume":"16","author":"M Hu","year":"2024","unstructured":"Hu, M. et al. Gut microbiome for predicting immune checkpoint blockade-associated adverse events. Genome Med. 16, 16 (2024).","journal-title":"Genome Med."},{"key":"1019_CR51","doi-asserted-by":"publisher","first-page":"1099063","DOI":"10.3389\/fcimb.2023.1099063","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front. Cell. Infect. Microbiol. 13, 1099063 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1019_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","volume":"15","author":"L Shojaie","year":"2024","unstructured":"Shojaie, L. et al. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 15, 140 (2024).","journal-title":"Cell Death Dis."},{"key":"1019_CR53","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/cancers14081913","volume":"14","author":"CLC Gudd","year":"2022","unstructured":"Gudd, C. L. C. & Possamai, L. A. The role of myeloid cells in hepatotoxicity related to cancer immunotherapy. Cancers 14, 1913 (2022).","journal-title":"Cancers"},{"key":"1019_CR54","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3389\/fimmu.2018.02948","volume":"9","author":"E Triantafyllou","year":"2018","unstructured":"Triantafyllou, E., Woollard, K. J., McPhail, M. J. W., Antoniades, C. G. & Possamai, L. A. The role of monocytes and macrophages in acute and acute-on-chronic liver failure. Front. Immunol. 9, 2948 (2018).","journal-title":"Front. Immunol."},{"key":"1019_CR55","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3389\/fimmu.2021.661182","volume":"12","author":"A Singanayagam","year":"2021","unstructured":"Singanayagam, A. & Triantafyllou, E. Macrophages in chronic liver failure: diversity, plasticity and therapeutic targeting. Front. Immunol. 12, 1086 (2021).","journal-title":"Front. Immunol."},{"key":"1019_CR56","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jhep.2022.02.028","volume":"77","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Transcriptional switch of hepatocytes initiates macrophage recruitment and T-cell suppression in endotoxemia. J. Hepatol. 77, 436\u2013452 (2022).","journal-title":"J. Hepatol."},{"key":"1019_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","volume":"75","author":"CLC Gudd","year":"2021","unstructured":"Gudd, C. L. C. et al. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. J. Hepatol. 75, 177\u2013189 (2021).","journal-title":"J. Hepatol."},{"key":"1019_CR58","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181\u20131190 (2018).","journal-title":"J. Hepatol."},{"key":"1019_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21572-y","volume":"12","author":"JA Hutchinson","year":"2021","unstructured":"Hutchinson, J. A. et al. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nat. Commun. 12, 1439 (2021).","journal-title":"Nat. Commun."},{"key":"1019_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2022.03.039","volume":"77","author":"S Chuah","year":"2022","unstructured":"Chuah, S. et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J. Hepatol. 77, 683\u2013694 (2022).","journal-title":"J. Hepatol."},{"key":"1019_CR61","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","volume":"24","author":"T Bartkowiak","year":"2018","unstructured":"Bartkowiak, T. et al. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27\u2013dependent pathway. Clin. Cancer Res. 24, 1138\u20131151 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1019_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217276","volume":"14","author":"T Affolter","year":"2019","unstructured":"Affolter, T. et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One 14, e0217276 (2019).","journal-title":"PLoS One"},{"key":"1019_CR63","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jhep.2021.06.037","volume":"75","author":"HP Llewellyn","year":"2021","unstructured":"Llewellyn, H. P. et al. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model. J. Hepatol. 75, 1083\u20131095 (2021).","journal-title":"J. Hepatol."},{"key":"1019_CR64","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hep.27549","volume":"61","author":"IG Metushi","year":"2015","unstructured":"Metushi, I. G., Hayes, M. A. & Uetrecht, J. Treatment of PD-1-\/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 61, 1332\u20131342 (2015).","journal-title":"Hepatology"},{"key":"1019_CR65","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1021\/acs.chemrestox.5b00137","volume":"28","author":"A Mak","year":"2015","unstructured":"Mak, A. & Uetrecht, J. The role of CD8 T cells in amodiaquine-induced liver injury in PD1\u2013\/\u2013 mice cotreated with anti-CTLA-4. Chem. Res. Toxicol. 28, 1567\u20131573 (2015).","journal-title":"Chem. Res. Toxicol."},{"key":"1019_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/1547691X.2018.1516014","volume":"16","author":"A Mak","year":"2019","unstructured":"Mak, A. & Uetrecht, J. Involvement of CCL2\/CCR2 macrophage recruitment in amodiaquine-induced liver injury. J. Immunotoxicol. 16, 28\u201333 (2019).","journal-title":"J. Immunotoxicol."},{"key":"1019_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008078","volume":"12","author":"CLC Gudd","year":"2024","unstructured":"Gudd, C. L. C. et al. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis. J. Immunother. Cancer 12, e008078 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1019_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246168","volume":"16","author":"K Adam","year":"2021","unstructured":"Adam, K., Iuga, A., Tocheva, A. S. & Mor, A. A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS One 16, e0246168 (2021).","journal-title":"PLoS One"},{"key":"1019_CR69","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"1019_CR70","doi-asserted-by":"publisher","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JR Patrinely","year":"2021","unstructured":"Patrinely, J. R. et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10, 1875639 (2021).","journal-title":"Oncoimmunology"},{"key":"1019_CR71","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","volume":"149","author":"A Miah","year":"2023","unstructured":"Miah, A. et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J. Cancer Res. Clin. Oncol. 149, 2235\u20132242 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1019_CR72","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","volume":"5","author":"E Atallah","year":"2023","unstructured":"Atallah, E. et al. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study. JHEP Rep. 5, 100851 (2023).","journal-title":"JHEP Rep."},{"key":"1019_CR73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana, R. J. et al. AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury. Hepatology 77, 1036\u20131065 (2023).","journal-title":"Hepatology"},{"key":"1019_CR74","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack, C. L. et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology 72, 671\u2013722 (2020).","journal-title":"Hepatology"},{"key":"1019_CR75","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/j.gastro.2024.01.049","volume":"166","author":"PJ Trivedi","year":"2024","unstructured":"Trivedi, P. J., Hirschfield, G. M., Adams, D. H. & Vierling, J. M. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: themes and concepts. Gastroenterology 166, 995\u20131019 (2024).","journal-title":"Gastroenterology"},{"key":"1019_CR76","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito, T. et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol. Int. 15, 1278\u20131287 (2021).","journal-title":"Hepatol. Int."},{"key":"1019_CR77","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.jhepr.2023.100719","volume":"5","author":"L Hountondji","year":"2023","unstructured":"Hountondji, L. et al. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 5, 100719 (2023).","journal-title":"JHEP Rep."},{"key":"1019_CR78","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3390\/jcm12113751","volume":"12","author":"L Parlati","year":"2023","unstructured":"Parlati, L. et al. Histological characteristics and management of hepatitis on immune checkpoint inhibitors: a retrospective descriptive study. J. Clin. Med. 12, 3751 (2023).","journal-title":"J. Clin. Med."},{"key":"1019_CR79","doi-asserted-by":"publisher","first-page":"E858","DOI":"10.1097\/MEG.0000000000002280","volume":"33","author":"B Pi","year":"2021","unstructured":"Pi, B. et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur. J. Gastroenterol. Hepatol. 33, E858\u2013E867 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1019_CR80","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cgh.2023.12.008","volume":"22","author":"L Meunier","year":"2024","unstructured":"Meunier, L. et al. Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data. Clin. Gastroenterol. Hepatol. 22, 1542\u20131545.e4 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1019_CR81","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3748\/wjg.14.3781","volume":"14","author":"JR Hov","year":"2008","unstructured":"Hov, J. R., Boberg, K. M. & Karlsen, T. H. Autoantibodies in primary sclerosing cholangitis. World J. Gastroenterol. 14, 3781 (2008).","journal-title":"World J. Gastroenterol."},{"key":"1019_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-021-00529-y","volume":"19","author":"J-M L\u00f6hr","year":"2022","unstructured":"L\u00f6hr, J.-M., Vujasinovic, M., Rosendahl, J., Stone, J. H. & Beuers, U. IgG4-related diseases of the digestive tract. Nat. Rev. Gastroenterol. Hepatol. 19, 185\u2013197 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1019_CR83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama, T. et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J. Gastroenterol. 26, 353 (2020).","journal-title":"World J. Gastroenterol."},{"key":"1019_CR84","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bcp.15243","volume":"89","author":"W Lu","year":"2023","unstructured":"Lu, W., Tang, B., Guo, Q., Zhao, Z. & Liu, L. Cholecystitis and cholangitis associated with lenvatinib: a pharmacovigilance study. Br. J. Clin. Pharmacol. 89, 579\u2013581 (2023).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1019_CR85","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/thy.2019.0355","volume":"30","author":"A Nervo","year":"2020","unstructured":"Nervo, A. et al. Symptomatic biliary disorders during lenvatinib treatment for thyroid cancer: an underestimated problem. Thyroid 30, 229\u2013236 (2020).","journal-title":"Thyroid"},{"key":"1019_CR86","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger, J. M. et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J. Clin. Oncol. 40, 1474 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1019_CR87","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","volume":"22","author":"AS Betof","year":"2017","unstructured":"Betof, A. S. et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist 22, 963\u2013971 (2017).","journal-title":"Oncologist"},{"key":"1019_CR88","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905\u20131912 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1019_CR89","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/M20-3419","volume":"174","author":"MK Van der Kooij","year":"2021","unstructured":"Van der Kooij, M. K. et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study. Ann. Intern. Med. 174, 641\u2013648 (2021).","journal-title":"Ann. Intern. Med."},{"key":"1019_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos, F. X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21\u201329 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1019_CR91","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison, A. et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 71, 2100\u20132111 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1019_CR92","doi-asserted-by":"publisher","first-page":"1326078","DOI":"10.3389\/fimmu.2023.1326078","volume":"14","author":"L Kocheise","year":"2024","unstructured":"Kocheise, L. et al. PD-1\/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Front. Immunol. 14, 1326078 (2024).","journal-title":"Front. Immunol."},{"key":"1019_CR93","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","volume":"28","author":"S Groha","year":"2022","unstructured":"Groha, S. et al. Germline variants associated with toxicity to immune checkpoint blockade. Nat. Med. 28, 2584 (2022).","journal-title":"Nat. Med."},{"key":"1019_CR94","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","volume":"28","author":"CA Taylor","year":"2022","unstructured":"Taylor, C. A. et al. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 2592\u20132600 (2022).","journal-title":"Nat. Med."},{"key":"1019_CR95","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","volume":"107","author":"O Hasan Ali","year":"2019","unstructured":"Hasan Ali, O. et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer 107, 8\u201314 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1019_CR96","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/hepr.13878","volume":"53","author":"S Kaneko","year":"2023","unstructured":"Kaneko, S. et al. Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatol. Res. 53, 450\u2013459 (2023).","journal-title":"Hepatol. Res."},{"key":"1019_CR97","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492 (2017).","journal-title":"Lancet"},{"key":"1019_CR98","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/hep.32468","volume":"76","author":"A D\u2019Alessio","year":"2022","unstructured":"D\u2019Alessio, A. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology 76, 1000\u20131012 (2022).","journal-title":"Hepatology"},{"key":"1019_CR99","doi-asserted-by":"publisher","first-page":"669150","DOI":"10.3389\/fimmu.2021.669150","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. Modulation of gut microbiota to enhance effect of checkpoint inhibitor immunotherapy. Front. Immunol. 12, 669150 (2021).","journal-title":"Front. Immunol."},{"key":"1019_CR100","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545 (2022).","journal-title":"Nat. Med."},{"key":"1019_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).","journal-title":"Nat. Commun."},{"key":"1019_CR102","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804\u20131808 (2018).","journal-title":"Nat. Med."},{"key":"1019_CR103","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000528698","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Adverse events of immune checkpoint inhibitor-based therapies for unresectable hepatocellular carcinoma in prospective clinical trials: a systematic review and meta-analysis. Liver Cancer 12, 521\u2013538 (2022).","journal-title":"Liver Cancer"},{"key":"1019_CR104","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.annonc.2023.12.008","volume":"35","author":"AB El-Khoueiry","year":"2024","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann. Oncol. 35, 381\u2013391 (2024).","journal-title":"Ann. Oncol."},{"key":"1019_CR105","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","volume":"80","author":"C Celsa","year":"2024","unstructured":"Celsa, C. et al. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J. Hepatol. 80, 431\u2013442 (2024).","journal-title":"J. Hepatol."},{"key":"1019_CR106","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.jhep.2024.01.008","volume":"81","author":"L Meunier","year":"2024","unstructured":"Meunier, L. et al. irLI or not irLI: that is the question. J. Hepatol. 81, e30\u2013e32 (2024).","journal-title":"J. Hepatol."},{"key":"1019_CR107","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00262-023-03390-x","volume":"72","author":"CL Han","year":"2023","unstructured":"Han, C. L. et al. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients. Cancer Immunol. Immunother. 72, 1957\u20131969 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"1019_CR108","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","volume":"15","author":"M Biewenga","year":"2021","unstructured":"Biewenga, M. et al. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol. Int. 15, 510\u2013519 (2021).","journal-title":"Hepatol. Int."},{"key":"1019_CR109","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s10238-022-00938-6","volume":"23","author":"JC Tian","year":"2023","unstructured":"Tian, J. C. et al. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. Clin. Exp. Med. 23, 2115\u20132129 (2023).","journal-title":"Clin. Exp. Med."},{"key":"1019_CR110","doi-asserted-by":"publisher","first-page":"105074","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst, S. M. et al. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. EBioMedicine 102, 105074 (2024).","journal-title":"EBioMedicine"},{"key":"1019_CR111","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","volume":"30","author":"AJ Schoenfeld","year":"2019","unstructured":"Schoenfeld, A. J. et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann. Oncol. 30, 839\u2013844 (2019).","journal-title":"Ann. Oncol."},{"key":"1019_CR112","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/1759-7714.13363","volume":"11","author":"O Yamaguchi","year":"2020","unstructured":"Yamaguchi, O. et al. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non\u2010small cell lung cancer harboring EGFR mutation. Thorac. Cancer 11, 1045 (2020).","journal-title":"Thorac. Cancer"},{"key":"1019_CR113","first-page":"100213","volume":"2","author":"P Begum","year":"2021","unstructured":"Begum, P., Goldin, R. D., Possamai, L. A. & Popat, S. Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report. JTO Clin. Res. Rep. 2, 100213 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"1019_CR114","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1019_CR115","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"1019_CR116","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/cts.13544","volume":"16","author":"B Sangro","year":"2023","unstructured":"Sangro, B. et al. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clin. Transl. Sci. 16, 1445\u20131457 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1019_CR117","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jitc-2019-000391","volume":"8","author":"PA Ascierto","year":"2020","unstructured":"Ascierto, P. A. et al. Original research: overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg\/kg with 3 mg\/kg in patients with advanced melanoma. J. Immunother. Cancer 8, 391 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1019_CR118","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto, P. A. et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 18, 611\u2013622 (2017).","journal-title":"Lancet Oncol."},{"key":"1019_CR119","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"1019_CR120","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis, G. V. et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J. Hepatol. 77, 1670\u20131689 (2022).","journal-title":"J. Hepatol."},{"key":"1019_CR121","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12072-022-10450-4","volume":"17","author":"J Lei","year":"2023","unstructured":"Lei, J. et al. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatol. Int. 17, 281\u2013290 (2023).","journal-title":"Hepatol. Int."},{"key":"1019_CR122","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/cncr.35175","volume":"130","author":"J Hong","year":"2024","unstructured":"Hong, J. et al. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B. Cancer 130, 1693\u20131701 (2024).","journal-title":"Cancer"},{"key":"1019_CR123","unstructured":"Institutes of Health Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. 2017 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (2017)."},{"key":"1019_CR124","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cgh.2015.10.007","volume":"14","author":"MJW McPhail","year":"2016","unstructured":"McPhail, M. J. W., Farne, H., Senvar, N., Wendon, J. A. & Bernal, W. Ability of King\u2019s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: a meta-analysis. Clin. Gastroenterol. Hepatol. 14, 516\u2013525.e5 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1019_CR125","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/apt.15413","volume":"50","author":"I Tsung","year":"2019","unstructured":"Tsung, I. et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment. Pharmacol. Ther. 50, 800\u2013808 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1019_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253070","volume":"16","author":"M Cunningham","year":"2021","unstructured":"Cunningham, M. et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS One 16, e0253070 (2021).","journal-title":"PLoS One"},{"key":"1019_CR127","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/jgh.14889","volume":"35","author":"K Sawada","year":"2020","unstructured":"Sawada, K. et al. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J. Gastroenterol. Hepatol. 35, 1042\u20131048 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1019_CR128","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/ (2012)."},{"key":"1019_CR129","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2023.7013","volume":"21","author":"M Li","year":"2023","unstructured":"Li, M. et al. Early liver specialist consultation is associated with faster biochemical resolution of severe immune checkpoint inhibitor-induced hepatitis. J. Natl Compr. Cancer Netw. 21, 617\u2013626 (2023).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1019_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2022. J. Natl Compr. Cancer Netw. 20, 387\u2013405 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1019_CR131","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1019_CR132","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan, M., Wang, Y., Rubio-Tapia, A. & Lim, J. K. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160, 1384\u20131393 (2021).","journal-title":"Gastroenterology"},{"key":"1019_CR133","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin, E., Michot, J. M., Rosmorduc, O., Guettier, C. & Samuel, D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2, 100170 (2020).","journal-title":"JHEP Rep."},{"key":"1019_CR134","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"T Peeraphatdit","year":"2020","unstructured":"Peeraphatdit, T. et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 72, 315\u2013329 (2020).","journal-title":"Hepatology"},{"key":"1019_CR135","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/apt.17898","volume":"59","author":"M Riveiro-Barciela","year":"2024","unstructured":"Riveiro-Barciela, M. et al. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury. Aliment. Pharmacol. Ther. 59, 865\u2013876 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1019_CR136","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2024.02.006","volume":"22","author":"M Li","year":"2024","unstructured":"Li, M. et al. Outcomes of high-grade immune checkpoint inhibitor hepatitis in hospitalized and nonhospitalized patients. Clin. Gastroenterol. Hepatol. 22, 1444\u20131452.e4 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1019_CR137","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer, M., Koukoulioti, E., Beyer, S., Simon, J. C. & Berg, T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J. Hepatol. 66, 657\u2013659 (2017).","journal-title":"J. Hepatol."},{"key":"1019_CR138","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.32215","volume":"75","author":"M Li","year":"2022","unstructured":"Li, M. et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology 75, 531\u2013540 (2022).","journal-title":"Hepatology"},{"key":"1019_CR139","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/jca.87335","volume":"14","author":"AP Machado","year":"2023","unstructured":"Machado, A. P. et al. The safety of immunosuppressants used in the treatment of immune-related adverse events due to immune checkpoint inhibitors: a systematic review. J. Cancer 14, 2956\u20132963 (2023).","journal-title":"J. Cancer"},{"key":"1019_CR140","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo, M. et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63, 1490\u20131493 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"1019_CR141","doi-asserted-by":"publisher","first-page":"E2340695","DOI":"10.1001\/jamanetworkopen.2023.40695","volume":"6","author":"I Van Buren","year":"2023","unstructured":"Van Buren, I. et al. Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy. JAMA Netw. Open 6, E2340695 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1019_CR142","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1136\/jitc-2023-007409","volume":"12","author":"E Daetwyler","year":"2024","unstructured":"Daetwyler, E. et al. Corticosteroid-resistant immune-related adverse events: a systematic review. J. Immunother. Cancer 12, 7409 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1019_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1624","volume":"5","author":"M Ueno","year":"2022","unstructured":"Ueno, M. et al. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review. Cancer Rep. 5, e1624 (2022).","journal-title":"Cancer Rep."},{"key":"1019_CR144","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/imt-2023-0085","volume":"15","author":"SB Ali","year":"2023","unstructured":"Ali, S. B. et al. Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. Immunotherapy 15, 1125\u20131132 (2023).","journal-title":"Immunotherapy"},{"key":"1019_CR145","first-page":"5908411","volume":"2022","author":"S Al-Nattah","year":"2022","unstructured":"Al-Nattah, S., Sharma, K. L., Caldis, M., Spengler, E. & Rose, W. N. Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation. Case Rep. Hepatol. 2022, 5908411 (2022).","journal-title":"Case Rep. Hepatol."},{"key":"1019_CR146","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","volume":"70","author":"M Riveiro-Barciela","year":"2019","unstructured":"Riveiro-Barciela, M. et al. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J. Hepatol. 70, 564\u2013566 (2019).","journal-title":"J. Hepatol."},{"key":"1019_CR147","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille, C. et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 6, 865\u2013871 (2020).","journal-title":"JAMA Oncol."},{"key":"1019_CR148","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini, F. C. et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol. Res. 6, 1093\u20131099 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1019_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen, J. et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J. Immunother. Cancer 8, e000604 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1019_CR150","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"1019_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-020-00301-4","volume":"15","author":"T Higuchi","year":"2021","unstructured":"Higuchi, T. et al. Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response. Hum. Genomics 15, 6 (2021).","journal-title":"Hum. Genomics"},{"key":"1019_CR152","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja, A. J. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig. Dis. Sci. 56, 545\u2013554 (2011).","journal-title":"Dig. Dis. Sci."},{"key":"1019_CR153","doi-asserted-by":"publisher","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","volume":"4","author":"G Mieli-Vergani","year":"2018","unstructured":"Mieli-Vergani, G. et al. Autoimmune hepatitis. Nat. Rev. Dis. Prim. 4, 18017 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1019_CR154","doi-asserted-by":"publisher","first-page":"102280","DOI":"10.1016\/j.eclinm.2023.102280","volume":"65","author":"JW Hahn","year":"2023","unstructured":"Hahn, J. W. et al. Global incidence and prevalence of autoimmune hepatitis, 1970\u20132022: a systematic review and meta-analysis. EClinicalMedicine 65, 102280 (2023).","journal-title":"EClinicalMedicine"},{"key":"1019_CR155","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver.","year":"2015","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 63, 971\u20131004 (2015).","journal-title":"J. Hepatol."},{"key":"1019_CR156","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.3748\/wjg.v20.i14.3986","volume":"20","author":"B Fosby","year":"2014","unstructured":"Fosby, B. HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation. World J. Gastroenterol. 20, 3986 (2014).","journal-title":"World J. Gastroenterol."},{"key":"1019_CR157","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen, T. H., Folseraas, T., Thorburn, D. & Vesterhus, M. Primary sclerosing cholangitis \u2014 a comprehensive review. J. Hepatol. 67, 1298\u20131323 (2017).","journal-title":"J. Hepatol."},{"key":"1019_CR158","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30006-2","volume":"1","author":"C Terao","year":"2019","unstructured":"Terao, C. et al. IgG4-related disease in the Japanese population: a genome-wide association study. Lancet Rheumatol. 1, e14\u2013e22 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1019_CR159","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","volume":"23","author":"T Rispens","year":"2023","unstructured":"Rispens, T. & Huijbers, M. G. The unique properties of IgG4 and its roles in health and disease. Nat. Rev. Immunol. 23, 763\u2013778 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1019_CR160","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus, C. L. et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 77, 659\u2013702 (2023).","journal-title":"Hepatology"},{"key":"1019_CR161","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/flgastro-2018-101001","volume":"10","author":"VS Hegade","year":"2019","unstructured":"Hegade, V. S., Sheridan, M. B. & Huggett, M. T. Diagnosis and management of IgG4-related disease. Frontline Gastroenterol. 10, 275\u2013283 (2019).","journal-title":"Frontline Gastroenterol."},{"key":"1019_CR162","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","volume":"134","author":"A Ghazale","year":"2008","unstructured":"Ghazale, A. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134, 706\u2013715 (2008).","journal-title":"Gastroenterology"},{"key":"1019_CR163","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman, M. H. et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 68, 1356\u20131378 (2019).","journal-title":"Gut"},{"key":"1019_CR164","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","volume":"80","author":"KN van Munster","year":"2024","unstructured":"van Munster, K. N., Bergquist, A. & Ponsioen, C. Y. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J. Hepatol. 80, 155\u2013168 (2024).","journal-title":"J. Hepatol."},{"key":"1019_CR165","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"O Chazouilleres","year":"2022","unstructured":"Chazouilleres, O. et al. EASL Clinical Practice Guidelines on sclerosing cholangitis. J. Hepatol. 77, 761\u2013806 (2022).","journal-title":"J. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01019-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T13:04:21Z","timestamp":1738242261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01019-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":165,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-01019-7","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"5 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}